A Comparative Study of Lipid-Lowering Effects of Guggul and Atorvastatin Monotherapy in Comparison to Their Combination in High Cholesterol Diet-Induced Hyperlipidemia in Rabbits

Das, Saibal Kumar; Datta, Ankur; Bagchi, Chiranjib; Chakraborty, Sandip; Mitra, Ashok; Tripathi, Santanu Kumar

doi:10.3109/19390211.2015.1118654

Cited by 13 publications

(7 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Atorvastatin is a commonly used cholesterol-lowering drug to treat hypercholesterolemia. It inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA), the enzyme that catalyzes the rate-limiting step of cholesterol synthesis 11 . To the best of our knowledge, no published study has linked GM alteration with atorvastatin treatment in a HFD-induced hypercholesterolemic rat model.…”

Section: Introductionmentioning

confidence: 99%

Effect of atorvastatin on the gut microbiota of high fat diet-induced hypercholesterolemic rats

Khan

Ahmed

Zamzami

et al. 2018

Sci Rep

View full text Add to dashboard Cite

The aim of the present study was to investigate alterations in gut microbiota associated with hypercholesterolemia and treatment with atorvastatin, a commonly prescribed cholesterol-lowering drug. In this study, seven experimental groups of rats were developed based on diets [high-fat diet (HFD) and normal chow diet (NCD)] and various doses of atorvastatin in HFD and NCD groups. 16S rRNA amplicon sequencing was used to analyze the gut microbiota. Atorvastatin significantly reduced the cholesterol level in treated rats. Bacterial diversity was decreased in the drug-treated NCD group compared to the NCD control, but atorvastatin-treated HFD groups showed a relative increase in biodiversity compared to HFD control group. Atorvastatin promoted the relative abundance of Proteobacteria and reduced the abundance of Firmicutes in drug-treated HFD groups. Among the dominant taxa in the drug-treated HFD groups, Oscillospira, Parabacteroides, Ruminococcus, unclassified CF231, YRC22 (Paraprevotellaceae), and SMB53 (Clostridiaceae) showed reversion in population distribution toward NCD group relative to HFD group. Drug-treated HFD and NCD groups both showed an increased relative abundance of Helicobacter. Overall, bacterial community composition was altered, and diversity of gut microbiota increased with atorvastatin treatment in HFD group. Reversion in relative abundance of specific dominant taxa was observed with drug treatment to HFD rats.

show abstract

Section: Introductionmentioning

confidence: 99%

Effect of atorvastatin on the gut microbiota of high fat diet-induced hypercholesterolemic rats

Khan

Ahmed

Zamzami

et al. 2018

Sci Rep

View full text Add to dashboard Cite

show abstract

“…This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis. 17 Especially, ATO has been recently reported to reverse the alteration of some specific dominant taxa induced by HFD in rats. 15 In this study we compared the hypocholesterolemia effects of 4 cholesterol-degrading probiotics: Pediococcus acidilactici JQII-5 (JQII-5), Pediococcus pentosaceus JQI-7(JQI-7), Lactobacillus plantarum LLY-606 (LLY-606) and Lactobacillus plantarum PC-26, 18 with ATO, and investigated the mechanisms by which they exerted hypochelesterolemic effects, focusing on their impact on gut microbiota.…”

Section: Introductionmentioning

confidence: 99%

Probiotic strains improve high-fat diet-induced hypercholesterolemia through modulating gut microbiota in ways different from atorvastatin

et al. 2019

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Probiotic strains improve high-fat diet-induced hypercholesterolemia through modulating gut microbiota in ways different from atorvastatin

Liu

Chen

et al. 2019

Preprint

View full text Add to dashboard Cite

Hypercholesterolemia is a major risk factor for cardiovascular disease (CVD). Probiotics is one of the most popular dietary supplements for hypercholesterolemia, but there are questions as to whether there are differences between probiotics and cholesterol-lowering drugs as like atorvastatin (ATO) both in effectiveness and the underlying mechanisms. In this study, the hypocholesterolemia effects of 4 probiotic strains were investigated and compared with ATO, focusing on their impacts on gut microbiota. Hypercholesterolemia model was established via high-fat diet (HFD) in golden hamsters after which ATO and the 4 probiotics were orally administered individually for 8 weeks. All probiotics were effective, but less than ATO, both on body weight, serum parameters (TG, TC, LDL, INS, HbA1c) and expression of inflammatory factors (TNF-α, IL-1β, CRP), with strain JQII-5 most significant. Besides, these effects were associated with restoration of the microbiota dysbiosis induced by HFD. It was worth noting that ATO and probiotics induced different shifts of gut microbiota in both structure and key phylotypes. Most interestingly, Allobaculum, a HFD-suppressed genus, reported to be involved in alleviating oxidative stress, was enriched by all tested probiotic strains, but not by ATO. Furthermore, Prevotella, also a HFD-suppressed genus, was uniquely reversed by JQII-5. Importantly, most of the alerted genus and reversed genus was found to be correlated to inflammatory state and serum lipid level. Compared with ATO, probiotic strains were less effective on body weight, hypercholesterolemia, and inflammation. However, probiotics exert additional favorable effects on gut microbiota, making them excellent potential complements to cholesterol-lowering drugs like ATO.

show abstract

A Comparative Study of Lipid-Lowering Effects of Guggul and Atorvastatin Monotherapy in Comparison to Their Combination in High Cholesterol Diet-Induced Hyperlipidemia in Rabbits

Abstract: Combination of atorvastatin and guggul was comparable to their monotherapies in improving lipid profile.

Cited by 13 publications

References 13 publications

Effect of atorvastatin on the gut microbiota of high fat diet-induced hypercholesterolemic rats

Effect of atorvastatin on the gut microbiota of high fat diet-induced hypercholesterolemic rats

Probiotic strains improve high-fat diet-induced hypercholesterolemia through modulating gut microbiota in ways different from atorvastatin

Probiotic strains improve high-fat diet-induced hypercholesterolemia through modulating gut microbiota in ways different from atorvastatin

Contact Info

Product

Resources

About